title: Severe anaphylactic reaction to infliximab: report of a case.
authors.forename: I
authors.initials: I
authors.lastname: Soykan
authors.forename: C
authors.initials: C
authors.lastname: Ertan
authors.forename: A
authors.initials: A
authors.lastname: Ozden
mesh_terms: D000328:Adult; D000707:Anaphylaxis / Q000139:chemically induced* / Q000628:therapy; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D002316:Cardiotonic Agents / Q000008:administration & dosage; D003424:Crohn Disease / Q000097:blood / Q000188:drug therapy; D004298:Dopamine / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000008:administration & dosage; D006634:Histamine H1 Antagonists / Q000008:administration & dosage; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D010102:Oxygen Inhalation Therapy; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D002316:Cardiotonic Agents; D005938:Glucocorticoids; D006634:Histamine H1 Antagonists; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D004298:Dopamine